Dolastatin 10 vs Plitidepsin
Head-to-head comparison of Dolastatin 10 (Dolastatin 10) and Plitidepsin (Dehydrodidemnin B (Plitidepsin)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Dolastatin 10 | Plitidepsin |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Dolastatin 10 | Dehydrodidemnin B (Plitidepsin) |
| Molecular Weight | 771.0 Da | 1110.3 Da |
| Half-Life | N/A | Approximately 44 hours |
| Amino Acids | 5 | N/A |
| Typical Dose | N/A in humans; subnanomolar to low-nanomolar in vitro | 1.5 mg/m2 IV |
| Route | Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 300 | 240 |
| Research Status | Pre-clinical | Clinical |
Dolastatin 10 Benefits
- ✓antineoplastic
- ✓microtubule disruption
- ✓antimitotic
- ✓ADC payload scaffold
Plitidepsin Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓anti-inflammatory
Dolastatin 10 Dosing
research-grade in vitro nanomolar use|early IV oncology exploration|no approved dosing regimen
Plitidepsin Dosing
1.5 mg/m2 IV infusion in oncology trials|q21d or similar intermittent schedules|dose escalation and combination protocols in studies
Dolastatin 10 Side Effects
- ⚠peripheral neuropathy
- ⚠neutropenia
- ⚠fatigue
Plitidepsin Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠transaminase elevation
Research Overview
Dolastatin 10
Dolastatin 10 became famous for extreme cytotoxic potency and its ability to block tubulin polymerization. Although the native compound itself did not become a standard therapy, it inspired a major class of clinically important auristatin-based payloads.
Plitidepsin
Plitidepsin has been studied for its ability to disrupt eEF1A-dependent pathways, induce oxidative stress, and suppress tumor cell growth. It has reached clinical oncology development and was also evaluated as a candidate against SARS-CoV-2 in the literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.